|
Fri, 10/24/2025 - 16:57 |
Sobi showcases new data across rare inflammatory conditions at ACR 2025 |
Swedish Orphan ... |
|
Tue, 10/21/2025 - 17:55 |
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report |
Swedish Orphan ... |
|
Tue, 10/21/2025 - 17:54 |
Sobi Q3 2025 report: Accelerated growth and portfolio momentum |
Swedish Orphan ... |
|
Wed, 09/10/2025 - 05:08 |
FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout |
Swedish Orphan ... |
|
Wed, 07/16/2025 - 05:31 |
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum |
Swedish Orphan ... |
|
Tue, 07/15/2025 - 15:35 |
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes |
Swedish Orphan ... |
|
Thu, 05/29/2025 - 17:46 |
Sobi to share new clinical data and research at EULAR 2025 |
Swedish Orphan ... |
|
Tue, 04/29/2025 - 06:52 |
Sobi publishes Q1 2025 report: Portfolio continues to deliver |
Swedish Orphan ... |
|
Wed, 04/23/2025 - 05:27 |
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit |
Swedish Orphan ... |
|
Wed, 03/19/2025 - 03:52 |
Sobi announces a new research collaboration on the development of Gamifant (emapalumab) in sepsis, which is to be presented at the ISICEM congress |
Swedish Orphan ... |
|
Thu, 02/27/2025 - 04:39 |
US FDA grants Priority Review to Sobis supplemental Biologics Licence Application (sBLA) for Gamifant (emapalumab-lzsg) |
Swedish Orphan ... |
|
Thu, 02/20/2025 - 04:33 |
EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN |
Swedish Orphan ... |
|
Wed, 02/05/2025 - 03:57 |
Sobi publishes Q4 2024 report: A solid ending to a strong year |
Swedish Orphan ... |
|
Thu, 08/08/2024 - 16:43 |
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN |
Swedish Orphan ... |
|
Thu, 07/18/2024 - 11:21 |
NEJM publishes ALTUVOCT phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A |
Swedish Orphan ... |
|
Tue, 07/16/2024 - 07:39 |
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance |
Swedish Orphan ... |
|
Wed, 06/19/2024 - 02:45 |
European Commission grants Sobi Marketing Authorisation for ALTUVOCT for treatment of haemophilia A |
Swedish Orphan ... |
|
Wed, 06/12/2024 - 06:16 |
Sobi to present new data across its haematology portfolio at the 2024 EHA congress |
Swedish Orphan ... |
|
Thu, 02/08/2024 - 07:08 |
Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024 |
Swedish Orphan ... |
|
Fri, 05/13/2022 - 06:33 |
Sobi to present new data in both PNH and ITP at the 2022 EHA congress |
Swedish Orphan ... |
|
Wed, 03/23/2022 - 09:29 |
Sobi to cease ReFacto manufacturing in the first quarter of 2024 |
Swedish Orphan ... |
|
Wed, 03/09/2022 - 11:35 |
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment |
Sanofi |
|
Fri, 02/04/2022 - 08:30 |
Sobi to present new data at EAHAD 2022 |
Swedish Orphan ... |
|
Wed, 12/15/2021 - 00:19 |
Aspaveli (pegcetacoplan) approved in EU as orphan drug for treatment of PNH |
Swedish Orphan ... |
|
Tue, 12/14/2021 - 06:49 |
Aspaveli/Empaveli (pegcetacoplan) demonstrated sustained normalisation of clinical measures in a broad PNH patient population |
Swedish Orphan ... |
